Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CRBP
stocks logo

CRBP

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-1.595
+104.49%
--
--
-1.462
+5.18%
--
--
-1.488
+3.33%
Estimates Revision
The market is revising No Change the revenue expectations for Corbus Pharmaceuticals Holdings, Inc. (CRBP) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 8.42%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-5.56%
In Past 3 Month
Stock Price
Go Up
up Image
+8.42%
In Past 3 Month
Wall Street analysts forecast CRBP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRBP is 44.38 USD with a low forecast of 28.00 USD and a high forecast of 53.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
Wall Street analysts forecast CRBP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRBP is 44.38 USD with a low forecast of 28.00 USD and a high forecast of 53.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 10.690
sliders
Low
28.00
Averages
44.38
High
53.00
Current: 10.690
sliders
Low
28.00
Averages
44.38
High
53.00
Stifel
Stephen Willey
Buy
maintain
$28 -> $32
2025-12-04
New
Reason
Stifel
Stephen Willey
Price Target
$28 -> $32
2025-12-04
New
maintain
Buy
Reason
Stifel analyst Stephen Willey raised the firm's price target on Crescent Biopharma to $32 from $28 and keeps a Buy rating on the shares. The firm believes the Kelun deal creates "greater pipeline and CR-001 development and optionality," with Crescent "securing ex-Greater China rights to an ADC with a clinically-validated target antigen and linker/payload and positioning itself to leverage data generated from Kelun's interrogation of CR-001-based combinations with its other ADCs."
RBC Capital
Brian Abrahams
Outperform
downgrade
$55 -> $53
2025-11-13
Reason
RBC Capital
Brian Abrahams
Price Target
$55 -> $53
2025-11-13
downgrade
Outperform
Reason
RBC Capital analyst Brian Abrahams lowered the firm's price target on Corbus Pharmaceuticals to $53 from $55 but keeps an Outperform rating on the shares. Following ESMO updates, the potential $500M sales opportunity for '701 in HNSCC and $350M sales opportunity in cervical cancer have been better de-risked, the analyst tells investors in a research note. RBC adds that investors are still not fully appreciating Corbus's potential large out-year sales opportunities across oncology and obesity.
Mizuho
NULL -> Outperform
maintain
$32 -> $39
2025-10-29
Reason
Mizuho
Price Target
$32 -> $39
2025-10-29
maintain
NULL -> Outperform
Reason
Mizuho raised the firm's price target on Corbus Pharmaceuticals to $39 from $32 and keeps an Outperform rating on the shares.
Piper Sandler
Overweight
maintain
$35 -> $51
2025-10-20
Reason
Piper Sandler
Price Target
$35 -> $51
2025-10-20
maintain
Overweight
Reason
Piper Sandler raised the firm's price target on Corbus Pharmaceuticals to $51 from $35 and keeps an Overweight rating on the shares. The firm says that the company's CRB-701 continues to look meaningfully active in heavily pre-treated HNSCC and cervical cancers in its Phase 1/2 ESMO update, with ORR of 48% in HNSCC and 38% in cervical at the 3.6 mg/kg dose - meaningfully higher than the bar set by Merus' petosemtamab in HNSCC and Tivdak in cervical.
Oppenheimer
Oppenheimer
Outperform -> Outperform
downgrade
$56 -> $53
2025-08-06
Reason
Oppenheimer
Oppenheimer
Price Target
$56 -> $53
2025-08-06
downgrade
Outperform -> Outperform
Reason
Oppenheimer lowered the firm's price target on Corbus Pharmaceuticals to $53 from $56 and keeps an Outperform rating on the shares. On Tuesday, the company reported Q2 results, highlighting updated clinical data for CRB-701 to be presented at ESMO in October for the Nectin-4 targeting ADC, the firm notes.
B. Riley
B. Riley
Buy
maintain
$28
2025-07-30
Reason
B. Riley
B. Riley
Price Target
$28
2025-07-30
maintain
Buy
Reason
B. Riley kept a Buy rating on Corbus Pharmaceuticals with a $28 price target following a transfer of coverage. The firm believes the company has a "promising" next-generation nectin-4 antibody drug conjugate with the potential to disrupt treatment paradigms in two "underserved" solid tumor types: head and neck and cervical cancer.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Corbus Pharmaceuticals Holdings Inc (CRBP.O) is -1.78, compared to its 5-year average forward P/E of -3.57. For a more detailed relative valuation and DCF analysis to assess Corbus Pharmaceuticals Holdings Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.57
Current PE
-1.78
Overvalued PE
3.64
Undervalued PE
-10.78

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.94
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.59
Undervalued EV/EBITDA
-3.46

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
77.83
Current PS
0.00
Overvalued PS
231.93
Undervalued PS
-76.27
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 2235.89% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 2235.89% over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

CRBP News & Events

Events Timeline

(ET)
2025-11-12
08:06:15
Corbus Pharmaceuticals projects financial stability through 2028
select
2025-11-12
08:05:01
Corbus Pharmaceuticals announces Q3 earnings per share of $1.90, surpassing consensus estimate of $1.71.
select
2025-10-31 (ET)
2025-10-31
07:36:34
Corbus Pharmaceuticals Prices 4.744 Million Share Spot Secondary Offering at $13.00
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
11-14Benzinga
RBC Capital Keeps Outperform Rating for Corbus Pharmaceuticals, Reduces Price Target to $53

  • Real-time Intelligence: Benzinga Pro offers fast and accurate stock market intelligence to help traders make informed decisions.

  • Exclusive Stories: The platform provides exclusive news stories generated by Benzinga reporters, enhancing the trading experience for its users.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing insights and strategies.

  • Trade Alerts: Users can receive the fastest news alerts to ensure they never miss a trading opportunity.

[object Object]
Preview
2.0
10-31Benzinga
Roku, SPS Commerce, Newell Brands, and Other Major Stocks Decline in Friday's Pre-Market Trading

  • U.S. Stock Futures: U.S. stock futures are mostly higher, with Nasdaq futures up over 1% on Friday morning.

  • Roku's Performance: Roku Inc. reported a 14% year-over-year increase in net revenue for Q3, totaling $1.211 billion, but shares fell 5% in pre-market trading.

  • Other Stocks Declining: Several companies, including SPS Commerce and Corbus Pharmaceuticals, saw significant drops in their stock prices due to mixed financial results and lowered guidance.

  • Market Reactions: Other notable declines in pre-market trading included Newell Brands and OneSpan, both of which reported disappointing Q3 results and reduced their FY25 guidance.

[object Object]
Preview
9.5
10-31Benzinga
Amazon Shares Surge Over 12%; Check Out 20 Stocks Making Moves in Premarket Trading

  • Amazon's Strong Performance: Amazon.com Inc reported third-quarter net sales of $180.2 billion, a 13% increase year-over-year, surpassing expectations, and its shares rose 12.5% in pre-market trading.

  • Fourth-Quarter Projections: The company anticipates fourth-quarter net sales between $206.0 billion and $213.0 billion, reflecting a year-over-year growth of 10% to 13%.

  • Pre-Market Stock Movements: Several stocks experienced significant pre-market trading movements, with DEFSEC Technologies Inc gaining 74.3% and Intensity Therapeutics Inc dropping 38.3%.

  • Mixed Results for Other Companies: Companies like SPS Commerce and Onespan reported disappointing financial results, leading to declines in their stock prices, while others like Alphatec Holdings Inc and Ardelyx Inc saw gains after better-than-expected quarterly results.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Corbus Pharmaceuticals Holdings Inc (CRBP) stock price today?

The current price of CRBP is 10.69 USD — it has increased 0.19 % in the last trading day.

arrow icon

What is Corbus Pharmaceuticals Holdings Inc (CRBP)'s business?

Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company. The Company has a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The Company’s oncology pipeline comprises two experimental drugs targeting solid tumors: CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFB expressed on cancer cells. CRB-701 is a monoclonal antibody attached to a monomethyl auristatin E (MMAE) cytotoxic payload using a proprietary linker technology. The pipeline also includes CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss.

arrow icon

What is the price predicton of CRBP Stock?

Wall Street analysts forecast CRBP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRBP is 44.38 USD with a low forecast of 28.00 USD and a high forecast of 53.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Corbus Pharmaceuticals Holdings Inc (CRBP)'s revenue for the last quarter?

Corbus Pharmaceuticals Holdings Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Corbus Pharmaceuticals Holdings Inc (CRBP)'s earnings per share (EPS) for the last quarter?

Corbus Pharmaceuticals Holdings Inc. EPS for the last quarter amounts to -1.90 USD, increased 65.22 % YoY.

arrow icon

What changes have occurred in the market's expectations for Corbus Pharmaceuticals Holdings Inc (CRBP)'s fundamentals?

The market is revising No Change the revenue expectations for Corbus Pharmaceuticals Holdings, Inc. (CRBP) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 8.42%.
arrow icon

How many employees does Corbus Pharmaceuticals Holdings Inc (CRBP). have?

Corbus Pharmaceuticals Holdings Inc (CRBP) has 28 emplpoyees as of December 05 2025.

arrow icon

What is Corbus Pharmaceuticals Holdings Inc (CRBP) market cap?

Today CRBP has the market capitalization of 187.64M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free